Valeant denies stealing trade secrets in M&A bid for lens tech by Eric Sagonowsky Thursday, August 17, 2017 Valeant hit back against eye-device maker Icon in legal fight over proprietary lens technology.
FDA generics push hits Valeant price-hike poster child Isuprel by Eric Sagonowsky Monday, August 7, 2017 Scott Gottlieb said his FDA would speed generics to market, and that effort boasts an early branded victim: Valeant’s controversial heart med Isuprel.
Hedge fund billionaire Paulson steps into middle of Valeant mess by Eric Sagonowsky Monday, June 19, 2017 Valeant Pharmaceuticals has added famed hedge fund manager John Paulson to its board.
Pharma shares shear Paulson's hedge funds deeply by Eric Palmer Tuesday, November 8, 2016 Drugs aren’t helping John Paulson much these days as shares in Valeant, Shire, Mylan, Allergan and Teva, take big cuts out of his hedge funds.
Hillary drug-price tweet tanks biopharma stocks again by Tracy Staton Thursday, August 25, 2016 The power of a Hillary Clinton tweet showed again Wednesday, when the presidential candidate spoke on drug price, raising fears of government action. Biotech stocks, pharma stocks--even U.K. drugmakers suffered.
